PDXK mutations cause polyneuropathy responsive to PLP supplementation by Chelban, V et al.
 
PDXK mutations cause polyneuropathy responsive to PLP supplementation 
Running head: Vitamin B6-responsive CMT 
 
Viorica Chelban MD, MSc1, 2*, Matthew P. Wilson PhD3#, Jodi Warman Chardon MD4,5,6#, Jana 
Vandrovcova PhD1#, M. Natalia Zanetti PhD7, Eleni Zamba‐Papanicolaou MD8,9, Stephanie 
Efthymiou MSc1, Simon Pope PhD10, Maria R Conte PhD11 , Giancarlo Abis PhD11, Yo‐Tsen Liu 
PhD12,13,14, Eloise Tribollet Ms1, Nourelhoda A. Haridy MD1,15, Juan A Botía PhD16,17, Mina Ryten 
PhD16, 18, Paschalis Nicolaou PhD8,9, Anna Minaidou PhD8,9, Kyproula Christodoulou PhD8,9, Kristin 
D. Kernohan PhD6, 19, Alison Eaton MD6, Matthew Osmond MSc6, Yoko Ito PhD6,  Pierre Bourque 
MD4,5, James E.C. Jepson PhD 7, Oscar Bello PhD 7, Fion Bremner MD20, Carla Cordivari MD21, Mary 
M. Reilly MD, FRCP, FRCPI, PhD 1, Martha Foiani MSc21,22, Amanda Heslegrave PhD 22,23, Henrik 
Zetterberg PhD 22,23,24, 25, Simon J.R. Heales PhD 10, Nicholas W. Wood PhD 1,26, James E. Rothman 
PhD 7,27, Kym M Boycott MD PhD6, Philippa B. Mills PhD 3#, Peter T. Clayton PhD 3# and Henry 
Houlden PhD 1,26*# for the Care4Rare Canada Consortium6 and the SYNaPS Study Group28 
 
1Department of Neuromuscular Diseases, 7Department of Clinical and Experimental Epilepsy, 16Reta Lila 
Weston Research Laboratories, 22Department of Neurodegenerative Disease, UCL Queen Square Institute 
of Neurology, University College London, London WC1N 3BG, UK. 
2Department of Neurology and Neurosurgery, Institute of Emergency Medicine, Toma Ciorbă 1, 
2052 Chisinau, Republic of Moldova. 
3Genetics and Genomic Medicine, GOS Institute of Child Health, University College London, London WC1N 
1EH. 
4Department of Medicine (Neurology), University of Ottawa, 5Ottawa Hospital Research Institute, 
6Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, K1H 8L1, 
Canada Ontario, Canada 19Newborn Screening Ontario, Children's Hospital of Eastern Ontario, Ottawa, 
Canada. 
8The Cyprus Institute of Neurology and Genetics, 9Cyprus School of Molecular Medicine Nicosia, Cyprus. 
8The Cyprus Institute of Neurology and Genetics, 9Cyprus School of Molecular Medicine Nicosia, Cyprus. 
10Neurometabolic Unit, 20Neuro‐ophthalmology Department, 21Clinical Neurophysiology Department, 
26Neurogenetics Laboratory, National Hospital for Neurology and Neurosurgery, Queen Square, London, 
WC1N 3BG, UK 
11Randall Centre of Cell and Molecular Biophysics, School of Basic and Medical Biosciences, King’s College 
London, London SE1 1UL, UK 
12Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, 13National Yang‐Ming 
University School of Medicine, 14Institute of Brain Science, National Yang‐Ming University, Taipei, Taiwan 
15Department of Neurology and Psychiatry, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt 
17Department of Information and Communications Engineering, University of Murcia, Campus Espinardo, 
30100 Murcia, Spain 
18Department of Medical & Molecular Genetics, King's College London, Guy's Hospital, SE1 9RT, London, UK  
23UK Dementia Research Institute at UCL, London WC1N 3BG, UK 
24Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S‐431 80 Mölndal, Sweden 
25Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska 
Academy at the University of Gothenburg, S‐431 80 Mölndal, Sweden 
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ana.25524  
This article is protected by copyright. All rights reserved.
 Chelban et al  
27Department of Cell Biology, Yale School of Medicine, New Haven, CT 06520‐8002, USA 
28SYNaPS Study Group, see Supplemental data S6 for list of collaborators.  
# These authors contributed equally to the work.  
Key words: PDXK, polyneuropathy, optic atrophy, vitamin B6, pyridoxal kinase  
Title: 88 characters, Running head: 25 characters 
Word count: Abstract: 250, Introduction: 94, Discussion: 607, Body: 5508  
Figures: 4 (colour figures 4), Tables: 3  
*Correspondence to: v.chelban@ucl.ac.uk and h.houlden@ucl.ac.uk 
 
ABSTRACT 
Objective: To identify disease‐causing variants in autosomal recessive axonal 
polyneuropathy with optic atrophy and provide targeted replacement therapy.  
Methods: We performed genome‐wide sequencing, homozygosity mapping and 
segregation analysis for novel disease‐causing gene discovery. We used circular dichroism 
to show secondary structure changes and isothermal titration calorimetry to investigate 
the impact of variants on ATP‐binding. Pathogenicity was further supported by enzymatic 
assays and mass spectroscopy on recombinant protein, patient‐derived fibroblasts, 
plasma and erythrocytes. Response to supplementation was measured with clinical 
validated rating scales, electrophysiology and biochemical quantification.  
Results: We identified bi‐allelic mutations in PDXK in five individuals from two unrelated 
families with primary axonal polyneuropathy and optic atrophy. The natural history of 
this disorder suggests that untreated, affected individuals become wheelchair‐bound and 
blind. We identified conformational rearrangement in the mutant enzyme around the 
ATP‐binding pocket. Low PDXK ATP‐binding resulted in decreased erythrocyte PDXK 
activity and low pyridoxal 5’‐phosphate (PLP) concentrations. We rescued the clinical and 
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biochemical profile with PLP supplementation in one family, improvement in power, pain 
and fatigue contributing to patients regaining their ability to ambulate during the first 
year of PLP normalization. 
Interpretation: We show that mutations in PDXK cause autosomal recessive axonal 
peripheral polyneuropathy leading to disease via reduced PDXK enzymatic activity and 
low PLP. We show that the biochemical profile can be rescued with PLP supplementation 
associated with clinical improvement. As B6 is a cofactor in diverse essential biological 
pathways, our findings may have direct implications for neuropathies of unknown 
aetiology characterised by reduced PLP levels. 
INTRODUCTION 
Peripheral neuropathies are amongst the most common neurological disorders 
worldwide affecting approximately 20 million people in Europe and USA alone with few 
disease‐modifying treatments established for these conditions1‐3. Inherited forms of 
peripheral neuropathies affecting both the motor and sensory nerves, known as Charcot‐
Marie‐Tooth (CMT) disease, are the most common genetic neuromuscular disorders 
affecting approximately 1 in 2500 people4‐8. However, only 25% of all autosomal 
recessive (AR) CMT cases have causal variants identified9 and treatment is only 
supportive1‐3. Most known genes associated with AR CMT cause disease either by 
affecting the cytoskeleton or axonal trafficking2.  
 
METHODS 
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Study participants 
Patients with polyneuropathy and optic atrophy were identified by neurogeneticists at 
the National Hospital for Neurology and Neurosurgery London and The Children’s 
Hospital of Eastern Ontario. The affected cases were recruited along with unaffected 
family members under IRB/ethics‐approved research protocols (UCLH: 04/N034; CHEO: 
CTO/1577) with informed consent. All cases had extensive genetic, metabolic and 
mitochondrial investigations carried out that excluded acquired and other inherited 
causes of polyneuropathy and optic atrophy.   
 
Phenotype and clinical measures  
All cases had comprehensive phenotyping performed by neurogenetics specialists 
including clinical assessment, electrophysiology, neuroimaging and videography. Motor 
function was quantified using the Medical Research Council (MRC) muscle scale, a 
standardised scale for the assessment of peripheral nervous system that grades muscle 
power from 0 to 5 in six validated movements and provides a total score out of a possible 
60 points. The disease severity and progression was assessed using validated 
Neurological Impairment Scale (NIS)10 and the Charcot‐Marie‐Tooth neuropathy score 2 
(CMTNS2). CMTNS2 is a reliable and valid composite of symptoms (three items), signs 
(four items), and neurophysiology (two items). It is designed to measure length‐
dependent motor and sensory impairment in genetic neuropathies11; 12. The NIS forms 
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part of the standard minimum dataset for the Functional Independence Measure and UK 
Functional Assessment Measure (UK FIM+FAM). It records severity of functional 
impairment (rated 0‐3) across 13 domains mapped onto the International Classification of 
Functioning (ICF). The score range is 0‐50. The affected individuals from family 1 had MRC 
scales, CMTNS2 and NIS assessment before and after replacement therapy.  
 
Genome-wide sequencing and haplotype analysis 
DNA was extracted from peripheral blood. Whole Genome Sequencing was performed 
by deCODE genetics, Inc. using DNA from the two affected siblings from family 1. 
Illumina HiSeq4000 instrument (Illumina, San Diego, CA, USA) was used to generate 100 
bp paired‐end reads. Alignment was performed using BWA  (http://bio‐
bwa.sourceforge.net/)13 with GRCH37 as a reference. Variants were called using the 
GATK 14-17 Unified Genotyper‐based pipeline14‐16 workflow. All variants were annotated 
using ANNOVAR18 and filtered using custom R scripts. Shared regions of homozygosity 
were identified using HomozygosityMapper19 and Bcftools/RoH20. Only novel or very 
rare variants with a minor allele frequency (MAF) of < 0.01 in the 1000 Genomes 
Project21, NHLBI GO Exome Sequencing22, and Exome Aggregation Consortium database 
(ExAC)23 were included.  Coding/splicing, homozygous variants that were within the 
autozygome of the affected cases were prioritized.  
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Whole exome sequencing (WES) was performed in family 2 using DNA from both 
affected siblings and their mother as part of the Care4Rare Canada Consortium. Exonic 
DNA was selected using the Agilent SureSelect Clinical Research Exome V1 kit, then 
sequenced on an Illumina NextSeq 500 with 2x150bp chemistry.  Read alignment, variant 
calling, and annotation were done as outlined for previous FORGE and Care4Rare 
Canada projects24.  Average coverage for the exomes was 182x, 190x, and 244x and 
>97% of consensus coding sequences exons in all exomes were covered at >10×. 
Sanger sequencing 
The variants identified by WGS and WES were confirmed by Sanger sequencing. The 
region was amplified using the following primers: 5’‐AGGAGGATCAGGGATGGGAG‐3’ and 
  5’‐CTCTCATATCCTGCTCCCCA‐3’ in family 1 and 5’‐CTTGCCGCTCTATGTTTGGAC‐3’ and 
  5’‐GAGAGTGACAGGCGCAACTC‐3’ in family 2. The promoter region of PDXK was 
amplified using the following primers: 5’‐GCGGTTCCCTTGGGTATC‐3’ and 5’‐
ACGCCTCCTTCTGACCTC‐3’. Genomic DNA was extracted from dried blood spots from 
affected individuals from family 1 and controls using the QIAamp DNA Micro Kit and from 
blood from family 2. Sequencing reactions were performed using the BigDye Terminator 
1.1 system (ThermoFisher, Paisley, UK) followed by sequencing using an ABI DNA 
Analyser (ThermoFisher, Paisley, UK). Electropherograms were analysed using the 
Sequencher software package (Gene Codes, MI, USA). 
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Gene co-expression analysis  
We generated Gene Co‐expression Networks (GCN) for CNS and PNS tissue‐specific 
transcriptomic data generated by the Genotype‐Tissue Expression Consortium25 (GTEx7 
V6 gene expression data accessible from https://www.gtexportal.org/). We analysed 
each of the tissue sample sets separately by filtering genes on the basis of an RPKM > 0.1 
(observed in > 80% of the samples for a given tissue). We then corrected for batch 
effects, age, gender and RIN using ComBat26. Finally, we used the residuals of these linear 
regression models to construct gene co‐expression networks for each tissue using 
WGCNA27and post‐processing with k‐means28 to improve gene clustering. Gene modules 
were functionally annotated with gProfileR4 R package using the Gene Ontology (GO) 
database without Electronic Inferred Annotations (EIA) and accounting for multiple 
testing with gSCS29. The top down plot figure is done with Cytoscape 3.5.130. We initially 
selected the 50 most connected genes within the black module, for the co‐expression 
network of tibial nerve, based on adjacency values. We included all connections between 
genes. Then we filtered out the connections with weight <0.05. Finally, we applied a 
Kamada‐Kawai layout algorithm to the remaining genes and edges to dispose them 
spatially at the canvas so their relative positions reflect similarity in connections. 
 
Plasmid constructs 
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The human PDXK wild‐type (WT) and PDXK mutant p.Ala228Thr cDNA were purchased 
from Invitrogen and cloned into the plasmid pGEX6p‐1 (GE Healthcare, Piscataway, NJ) 
using the sites BamHI and NotI (New England Biolabs).  
 
Protein purification  
Escherichia coli strain Rosetta2 (DE3) (Novagen, Darmstadt, GER) was transformed with 
the plasmids pGEX6p‐1‐PDXK and pGEX6p‐1‐PDXK p.Ala228Thr and  grown at 37°C to an 
OD600nm of 0.8 and then induced with 0.5 mM Isopropyl β‐D‐1‐thiogalactopyranoside 
(IPTG) for 4 hours. Cells were lysed, using a cell disruptor, (Avestin, Ottawa, CA) in lysis 
buffer containing 25 mM HEPES, pH 7.4, 400 mM KCl, 4% Trition X‐100, 1 mM 1,4‐
dithiothreitol (Sigma‐Aldrich) and SIGMAFAST™ Protease Inhibitor Cocktail Tablets, EDTA‐
Free (Sigma‐Aldrich). The samples were supplemented with 5% polyethylamine (Sigma‐
Aldrich) and clarified using a 45Ti rotor (Beckman Coulter, Brea, CA) at 100,000 x g for 30 
min prior to incubation overnight at 4°C with Glutathione Agarose beads (Pierce, 
Rockford, IL) previously washed in lysis buffer containing 1% Triton X‐100. The 
Glutathione Agarose beads containing the immobilised proteins GST‐PDXK and PDXK 
p.Ala228Thr were subsequently washed in lysis buffer containing 1% Triton X‐100 and 
incubated with 10mg/ml DNAse and RNAse (Sigma‐Aldrich) for 1 hour at room 
temperature (RT), prior to washing in lysis buffer containing no Triton X‐100. The GST tag 
was cleaved using 100 U of PreScission Protease (GE Healthcare, Piscataway, NJ) for 2 
hours at RT. After elution the proteins were dialyzed in 25 mM HEPES, pH7.4, 100 mM 
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KCl, 1mM 1,4‐dithiothreitol overnight at 4°C. Protein concentration was determined using 
the BCA Protein Assay Kit (Thermo Fisher Scientific).  
 
Circular dichroism (CD)  
To investigate conformational differences between wild‐type PDXK and the disease‐
linked mutant p.Ala228Thr, circular dichroism (CD) analyses were performed. The 
extinction coefficients of both proteins  (ε280 = 31400 M‐1cm‐1) were calculated using the 
ProtParam tool within the ExPASy Portal31. Proteins were prepared as described above 
and dialysed overnight at 4oC in 30 mM TRIS pH 7, 100 mM KCl, 3 mM MgCl2, 0.5 mM 
TCEP. Samples were concentrated to 0.2 mg/mL using Amicon Ultra‐0.5 mL centrifugal 
filters (Merck).  
UV and CD spectra were acquired on the Applied Photophysics Ltd Chirascan Plus 
spectrometer across the 400‐190 nm wavelength region. 10 mm (400‐230 nm) and 0.5 
mm (260‐190 nm) strain‐free rectangular cells were employed.  The instrument was 
flushed continuously with pure evaporated nitrogen throughout the experiment.  The 
following parameters were employed: 2 nm spectral bandwidth, 1 nm step‐size and 1 s 
instrument measurement time‐per‐point. All spectra were acquired at 25oC, and buffer 
baseline corrected. Light scattering correction was applied on the UV spectra of both 
proteins using the Chirascan Pro‐Data Software (APL). Where possible, spectra were 
smoothed with a window factor of 4 using the Savitzky‐Golay method32 for better 
presentation.  
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The far‐UV CD spectra of the two proteins were corrected for concentration and 
pathlength and expressed in terms of Δε (M‐1cm‐1) per amino acid residue. Protein 
secondary structure content was assessed using the Principle Component Regression 
method based on 16 known protein structures31 embedded in the PLSPlus/IQ routine on 
the GRAMS32 AI software (Galactic, USA). 
Isothermal titration calorimetry (ITC)  
 The affinity of a non‐hydrolysable analogue of ATP, called Adenosine 5'‐(3‐
thiotriphosphate) tetralithium salt (ATPγS), for both PDXK WT and p.Ala228Thr mutant, 
was examined using a MicroCal Isothermal Titration Calorimeter ITC200 instrument 
(Malvern). Both proteins were prepared as described above in 30 mM TRIS pH 7, 100 mM 
KCl, 3 mM MgCl2, 0.5 mM TCEP (ITC buffer). An initial 0.2 M stock of ATPγS was prepared 
in water and diluted with ITC buffer to a final concentration of 250 μM. The 
concentration was adjusted using the UV Absorbance at 259 nm, and the extinction 
coefficient of 15.4 mM‐1cm‐1 suggested by the ligand provider (Jena Bioscience).  
The experiments were conducted at 25°C following standard procedures as described 
previously33.  40 μL of 250 µM ATPγS was titrated into a 330μL solution of 25 µM WT or 
p.Ala228Thr protein. The ITC experiment consisted of twenty 2μL injections with a 
spacing of 180 seconds. Heat produced by titrant dilution was obtained by a control 
experiment, titrating into buffer alone, under the same conditions.  
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The MicroCal‐Origin 7.0 software package was used to fit the integrated heat data 
obtained for the titrations corrected for heats of dilution, using a non‐linear least‐squares 
minimization algorithm based on an independent binding sites model. ΔH (reaction 
enthalpy change in kcal/mol), Ka (1/KD) (equilibrium association constant per molar) and 
n (molar ratio of the proteins in the complex) were the fitting parameters. The reaction 
entropy was calculated using the relationships ΔG = ΔH ‐TΔS = ‐RTln(1/KD).  
 
Western blotting 
Fibroblast samples from affected, carriers and healthy people were obtained with 
consent. After reaching 90% confluence, the cultured cells were harvested and lysed in 
ice cold lysis RIPA buffer containing 50mM Tris‐HCl pH 8.0, 150mM NaCl, 0.5% DOC, 0.1% 
Triton X‐100, 0.1% sodium dodecyl sulphate (SDS) and SIGMAFAST Protease Inhibitor 
Cocktail for 30 minutes. The lysate was then centrifuged at 16000 g at 4°C and the 
supernatant transferred to a new tube. The protein concentration was measured using 
the BCA protein assay kit (Pierce) according to manufacturer’s protocol. Equal amounts of 
protein (30 μg) from affected and healthy individuals were separated on a 10% SDS‐PAGE 
gel (NuPAGE Invitrogen) and transferred onto an Immobilon membrane (Millipore). After 
blocking the membrane with 2% fat free milk in PBS‐Tween for 1 hour at RT, the 
membrane was incubated with anti‐PDXK antibody (Abcam 38208; 1:500) for 1 hour at 
RT. The membranes were subsequently washed and incubated with horseradish 
peroxidase conjugated goat anti rabbit IgG (17210, Bio‐Rad Laboratories, 1:5,000) for 1h 
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at RT. Blots were developed using ECL Prime (GE Healthcare), visualized via a ChemiDoc 
Touch Imaging System and analysed using Image Lab 5.2 software (Bio‐Rad Laboratories). 
For the quantification, the signal intensity of each band corresponding to the PDXK WT 
and PDXK p.Ala228Thr mutant protein were normalized to the signal intensity of the 
corresponding reversible Ponceau staining as a reliable loading control34. The amount of 
PDXK WT and mutant protein were expressed as a percentage of the control sample. The 
experiment was repeated 3 times.  
Measurement of pyridoxal kinase activity 
The pyridoxal kinase activity present in dried blood spots (DBS) was determined by 
adapting the protocol used by Wilson et al35 with the following modifications. 3 mm discs 
punched from dried blood spots were incubated for 10 min at 37 °C with shaking at 300 
rpm in a reaction buffer containing 20 mmol/L potassium phosphate adjusted to pH 6.1, 
10 μmol/L pyridoxal and 300 μmol/L MgATP (all purchased from Sigma‐Aldrich, 
Gillingham, UK). The same method was adapted for the investigation of activity of the 
purified recombinant pyridoxal kinase. 5 μl of 20 ng/μl purified pyridoxal kinase protein 
lysate was placed in a UPLC 96‐well sample plate (Waters, Elstree, UK). Subsequently, 115 
μl of reaction buffer containing potassium phosphate (pH 6.1), pyridoxal and MgATP was 
added to create a final concentration of 20 mmol/L potassium phosphate, with pyridoxal 
and MgATP concentrations adjusted as appropriate. Investigation of pyridoxal kinase 
kinetics as a function of pyridoxal concentration used a MgATP concentration of 300 
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μmol/L. A pyridoxal concentration of 50 μmol/L was utilised for the determination of 
pyridoxal kinase kinetics as a function of MgATP concentration. After reaction buffer 
addition, the plate was incubated for 10 min at 37 °C in an Eppendorf Thermomixer C 
with shaking at 300 rpm prior to addition of 120 μl of a reaction stop mix identical to that 
used for the determination of pyridoxamine 5’‐phosphate oxidase activity from dried 
blood spots. 
Dried blood spots (DBS) were collected from 4 affected cases and 22 controls (age 15 – 
92). Pyridoxal kinase activity of the recombinant proteins and that of dried blood spots 
was determined by using liquid chromatography‐tandem mass spectrometry (UPLC‐
MS/MS) to determine the formation of pyridoxal 5’‐phosphate after incubation of these 
with the enzyme substrate pyridoxal and expressed as µmol PLP L‐1 h‐1 from recombinant 
protein and as pmol PLP (3 mm DBS)−1 h–1 from dried blood spots.  
Data collection and statistical analysis were performed using Waters MassLynx and 
GraphPad Prism 6.0 software packages. 
 
UPLC-MS/MS measurement of the B6 vitamers 
B6 vitamer concentrations (pyridoxine (PN), pyridoxal (PL), PLP, pyridoxamine (PM), 
pyridoxamine phosphate (PMP)) and pyridoxic acid (PA) were quantified by ultra 
performance liquid chromatography‐tandem mass spectrometry (UPLC‐MS/MS) using 
stable isotope‐labelled internal standards35; 36.   
 
This article is protected by copyright. All rights reserved.
 Chelban et al  
 
HPLC measurement of B6 vitamers   
Pyridoxal phosphate was measured by HPLC with fluorescence detection using a 
Chromsystems kit as described previously35. Pyridoxic acid concentration was calculated 
using an external calibration standard. 
 
PLP measurements pre and post PLP-replacement 
Plasma PLP concentrations pre‐ and post PLP replacement were measured using two 
independent HPLC and UPLC‐MS/MS methods as described above to validate the results.  
The difference between groups was tested with the use of a one‐way analysis‐of‐variance 
test, followed by Tukey‐Kramer Test. The middle lines of the bars indicate mean values, 
±1 SD. 
 
Measurement of neurofilament light chain (NFL) concentration  
Plasma NFL concentration was measured by digital enzyme‐linked immunosorbent assay 
using the commercially available NF‐Light kit on a Single molecule array (Simoa) platform 
(HD‐1 Analyzer) according to instructions by the manufacturer (Quanterix, Lexington, 
MA). All measurements were performed in duplicates, in one round of experiments using 
one batch of reagents. Intra‐assay coefficients of variation were <10%.  
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RESULTS  
Here we describe five affected cases from two unrelated families (Figure 1A) with early, 
childhood‐onset sensorimotor, length dependent, predominantly axonal polyneuropathy 
and adult onset optic atrophy (Table 1).  
 
Disease characterization 
 
Family 1 is of Cypriot origin (affected individuals F1‐II‐5, currently 80 years, F1‐II‐6, 
currently 75 years and F1‐II‐9 died at 71 from an unrelated medical condition). Three 
affected siblings presented with difficulties running, distal wasting and weakness in the 
lower limbs before the age of 10 years, progression to upper limbs by age of 12 and onset 
of visual loss in their 40s. The disease progressed and at age of 79, case F1‐II‐5 required 
the assistance of two people for sit‐to‐stand, mobilising with the assistance of two plus 
zimmer‐frame for transfers and short distances, and using a wheelchair for all other 
activities. Neurogenic‐type pain, particularly in the lower limbs, was difficult to control 
despite multiple lines of symptomatic treatment. Case F1‐II‐6 (age 74) could only walk 
short distances with assistance from one individual. Neurological examination showed 
bilateral distal wasting from mid forearm and below the knee, with wasting of the thenar, 
hypothenar, intrinsic muscle of the hands, distal lower limbs muscles, pes cavus, and 
absent reflexes throughout in both patients (Figure 1B). The MRC muscle score was 44 (of 
60) in case F1‐II‐5 and F1‐II‐6. Strikingly, both patients had severely reduced sensation in 
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all limbs and in all modalities with profound joint position sense loss up to the knee and 
vibration loss up to the iliac crest in both cases (Table 1 and Supplemental data S1). 
Vision was reduced (including colour vision) and fundoscopy confirmed bilateral optic 
atrophy in both cases (Figure 1C).  The remaining cranial nerve examination was normal. 
The third sibling F1‐II‐9 (now deceased) was similarly affected.  
 
Family 2 is of Scottish (paternal) and Italian (maternal) origin with two affected sisters 
(patient F2‐II‐1, currently 31 years; patient F2‐II‐2, currently 29 years) who presented 
with childhood‐onset of a mild decrease in balance, which progressed to difficulty with 
running in adolescence, and progression to mild distal hand weakness the 3rd decade. 
Both sisters ambulate independently without aides and neither sister has symptoms of 
visual loss at their present ages. Neurological examination showed mild symmetrical 
distal wasting in hand intrinsic muscles and prominent distal lower limbs muscle wasting 
with pes cavus and mild hammertoes. There was mild distal weakness in hand intrinsics in 
the upper limbs and in the toes and distal lower legs and feet. The MRC scores were 56 
(F2‐II‐1) and 54 (F2‐II‐2). Both sisters were areflexic, with reduced pinprick in the lower 
extremities and decreased vibration to the knees (Table 1 and Supplemental data S1). 
Colour vision was reduced. Fundoscopy confirmed bilateral optic atrophy in both cases; 
the remainder of the cranial nerve examination was normal.  
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Nerve conduction studies (NCS) in all affected cases revealed a progressive length‐
dependent, sensorimotor, predominantly axonal neuropathy (Supplemental data S2). 
Early in the disease (as seen in family 2) the NCS show a predominantly axonal 
neuropathy affecting mainly the lower limbs with absent sensory responses. Mild 
conduction slowing with normal motor responses was recorded in the upper limbs. The 
natural history of this disorder in the older individuals from family 1 (F1‐II‐5 and F1‐II‐6) 
with data recorded over 20 years of disease duration suggests that untreated, the 
neuropathy progresses in a length‐dependent fashion and is characterised by prolonged 
DMLs, severe reduction of CMAPs in addition to absent sensory responses affecting 
upper and lower limbs as confirmed on NCS. Interestingly, both patients present with 
significantly more prolonged DML in the median compared to ulnar nerve (6.1 vs 3.6 ms). 
While it is possible that this is secondary to long‐standing median compression lesion at 
the wrist we cannot exclude that this finding is disease‐related. The reduced CMAPs were 
associated with reduction of conduction velocities in the intermediate range mainly in 
the median nerves. Electromyography in all cases tested was consistent with chronic 
denervation with no myopathic changes.  
 
To further ascertain the exact type of neuropathy we performed a nerve biopsy in case 
F1‐II‐6. It showed diffuse and severe depletion of both small and large myelinated axons 
with regenerating clusters but no “onion bulbs”. This confirms a long‐standing 
axonopathy with no overt demyelination (Figure 1D).  
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All cases reported here had pale optic discs on clinical examination. We performed visual 
evoked potentials (VEPs) to further describe the involvement of the optic nerve in the 
course of disease. We found that VEPs in case F1‐II‐6 have decreased considerably in 
amplitude from 7.9 and 7.4 in each eye to 1.8 and 1.9 over 20 years period indicating 
axonal loss and bilateral visual pathway involvement (Supplemental data S2). Similar 
results were confirmed in case F1‐II‐5. Family 2 has not been investigated with VEPs. 
 
Identification of disease-causing PDXK variants 
Previous extensive genetic37, metabolic and mitochondrial investigations failed to identify 
any acquired, or known causes of inherited polyneuropathy in all cases. Whole genome 
sequencing (WGS) and homozygosity mapping in family 1 revealed a homozygous region 
on chromosome 21 with a shared region from 42‐45 Mb on chromosome 21. This region 
included a shared homozygous variant in the two affected siblings that was carried by 
unaffected family members in heterozygous state: PDXK (NM_003681) c.682G>A 
(p.Ala228Thr). This variant was absent in 150 Cypriot controls. p.Ala228Thr is absent from 
the gnomAD database in homozygous state though reported in 7 heterozygous alleles (5 
South Asian and two European) from 250586  (total allele frequency of 0.00002793)23.   
 
Independently, homozygosity mapping in family 2 revealed a 1.35Mb region of 
homozygosity on chromosome 21. WES in family 2 identified a shared homozygous 
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variant in this region, the c.659G>A p.(Arg220Gln) in the two affected sisters and was 
carried by each parent. This variant is absent from gnomAD in homozygous state and 
reported in 5 heterozygous European alleles from 250146) (total allele frequency of 
0.00001999)23. It is predicted to be deleterious to protein function by in-silico programs 
(Combined Annotation Dependent Depletion (CADD) score 24). Sanger sequencing in 
affected individuals and carriers confirmed both variants (Figure 1E). 
 
PDXK is ubiquitously expressed in humans encoding for pyridoxal kinase (PDXK), a 
cytoplasmic protein that converts vitamin B6 to its active form, pyridoxal 5’‐phosphate 
(PLP) (Figure 1F). PLP is an essential cofactor for >70 human enzymes representing 
diverse, essential biological pathways including amino acid and neurotransmitter 
metabolism.  
 
Since PDXK mutations produce a peripheral rather than a predominantly central nervous 
system disease we investigated these differences further in-silico using public bulk 
tissue25 and cell‐specific transcriptomic data38. This demonstrated that human peripheral 
(tibial – mixed motor and sensory) nerve is amongst the tissues with the highest 
expression of PDXK (Figure 2A) with evidence for expression specifically in peripheral 
sensory neurons, based on single cell mouse transcriptomic data38 (Figure 2B).  This 
showed different co‐expression profiles in brain compared to peripheral nerve tissue. 
Weighted gene co‐expression analysis demonstrated that in 9 of 11 brain regions 
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analysed PDXK was co‐expressed with genes relating to synaptic transmission and 
neuronal identity whilst co‐expression data from the tibial nerve showed that PDXK was 
located within a module enriched for genes involved in oxidation‐reduction processes 
(GO:055114, FDR‐corrected p‐value = 2.36 x 10‐9) (Figure 2C and Supplemental S3).  
 
Assessment of the impact of PDXK variants on protein structure and enzymatic activity 
Arginine 220 and Alanine 228 are evolutionary conserved amino acids in eutherians 
(Figure 2D). Arginine 220 is located in the β9 in the vicinity of the ATP binding site39. 
Alanine 228 is located in the ATP‐binding pocket of pyridoxal kinase (Figure 2E) a critical 
region of the kinase, part of the loop region between strand β11 and helix α7 that rotates 
away from the active site allowing binding of the ATP adenine39. Whilst the Ala228 side‐
chain does not contact ATP directly, its backbone is involved in recruiting ATP to the 
catalytic pocket.  
 
Far‐UV circular dichroism (CD) spectra analysis of both WT and p.Ala228Thr revealed 
that, whilst both proteins were folded, there were small but significant differences in 
their secondary structure (Figure 3A).  WT PDXK had an estimated α‐helix and β‐strand 
content of 31.2% and 19% respectively; similar to previous X‐ray studies (PDB 3KEU)40. In 
the mutant protein a 26.0% and 21.1% of helical and strand content, respectively, was 
estimated, suggesting altered protein conformation. Furthermore, near‐UV CD analysis 
revealed distinctive CD fingerprints for wild‐type and p.Ala228Thr proteins, indicating 
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conformational rearrangements of aromatic side‐chains41 around the catalytic pocket, 
most likely hindering the enzyme’s ability to bind ATP. 
 
We performed isothermal titration calorimetry (ITC) confirming that p.Ala228Thr affected 
the ATP‐binding ability of PDXK. Interaction of wild‐type (WT) PDXK with the non‐
hydrolysable ATP analogue ATPγS generated well‐interpolated, sigmoid‐shaped curves, 
based on an independent and equivalent binding sites model centred on 1:1 
stoichiometry. By contrast, no association between p.Ala228Thr and ATPγS was observed 
(Figure 3B). 
 
Whilst no reduction in the expression of the mutant protein (p.Ala228Thr) compared to 
wild‐type PDXK in case‐derived fibroblasts was evident (Figure 3C), kinetic studies with 
human recombinant PDXK showed an approximate two‐fold increase in the Km of the 
p.Ala228Thr mutant protein (31.9 μmol/L) for pyridoxal compared to wild‐type protein  
(14.5 μmol/L) and a reduction in the Vmax of the mutant protein (p.Ala228Thr) to 0.95 
µmol L‐1 h‐1 compared to 2.52 µmol L‐1 h‐1 for wild‐type PDXK. Upon variation of MgATP 
concentration, sigmoidal kinetics were observed (WT k0.5 = 53.4 µmol/L; Vmax = 16.8 pmol 
h‐1, p.Ala228Thr k0.5 = 174.4 µmol/L; Vmax= 6.3 pmol h‐1) indicating cooperative binding 
between the two substrates, ATP and pyridoxal (Figure 3D‐E).  
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Analysis of erythrocyte PDKX activity from cases carrying the p.Arg220Gln and 
p.Ala228Thr substitutions further confirmed the deleterious effect of these variants on 
pyridoxal kinase activity (Figure 3F). The PDKX activity in the 4 affected cases was 
reduced (1.1 and 0.8 pmol DBS‐1 h‐1  in family 1 and 1.19 and 0.5 pmol DBS‐1 h‐1  in family 
2) relative to controls (2.6–14.7 pmol DBS‐1 h‐1, mean; 8.0). Heterozygote activity (n=1, F‐
1‐III‐1) was within normal range (4.9 pmol DBS‐1 h‐1). No correlation of DBS pyridoxal 
kinase activity with age was identified in controls. When segregated according to gender, 
a difference was identified between control males and females (9 male: mean=9.2 
range=5.9‐14.7; 12 female: mean=7.1 range=2.6‐11.7) that approached significance (P = 
0.1099 by untailed T test).  An insertion located in the erythyroid‐specific promoter 
region of pyridoxal kinase has been associated with reduced erythrocyte PDXK activity21.  
Sequencing this region showed that the reduced activity of all affected individuals was 
not attributable to this insertion 42 (Supplemental S4).  
 
Finally, we measured plasma PLP concentrations in all affected individuals. Plasma PLP 
was greatly reduced in cases carrying the p.Arg220Gln and p.Ala228Thr compared to age‐
matched controls (Figure 3G‐H). 
 
In order to quantify the axonal damage we measured the neurofilament light chain (NFL) 
protein in plasma from patients carrying PDXK mutations. NFL, a major axonal 
cytoskeletal protein, is released into cerebrospinal fluid (CSF) and blood during axonal 
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breakdown43 providing a dynamic biomarker of axonal damage in neurodegenerative 
disorders, including inherited neuropathies44. Both p.Arg220Gln and p.Ala228Thr variants 
were associated with high NFL (case F2‐II‐1: 49.6 pg/mL and in case F1‐II‐5: 25 pg/mL), 
within the range of NFL concentrations published for other axonal CMTs44. 
 
Supplementation with PLP is associated with biochemical correction and clinical 
improvement 
Based on clear pathogenicity of the PDXK mutation leading to low PLP, case F1‐II‐5 and 
F1‐II‐6 were treated with oral PLP. High doses of pyridoxine are known to be 
neurotoxic45, therefore we used PLP, which is hydrolysed to PL, to increase the upstream 
pyridoxal and force the flux with an enzyme with a high Km based on our results of 
recombinant p.Ala228Thr protein kinetics. We initiated PLP replacement with 50 mg/day 
PLP, a dose that was commonly used in adults taking pyridoxal 5'‐phosphate as a vitamin 
supplement with no reported side effects. We aimed to achieve plasma PLP 
concentration above the normal range by PLP replacement and this was achieved with 50 
mg/day. 
 
Two weeks after initiating the supplementation, plasma PLP levels had increased 
considerably without any side effects. PLP levels remained stable at 1, 3, 12, 18 and 24 
months on PLP replacement (Figure 4A‐B, Table 2) with improvement in symptoms 
(Supplemental data S5). Clinical improvement was noted after the first 3 months of PLP 
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replacement in the absence of any additional physiotherapy. Sensory examination and 
vision remained unchanged in both cases. Main motor improvements were in elbow and 
wrist flexion/extension and hip and knee flexion/extension with modest improvement in 
finger extension (Supplemental data S1) leading to 8 and 6 points improvement in the 
MRC sum score at 18 months on PLP replacement in case F1‐II‐5 and case F1‐II‐6, 
respectively. At last examination, 24 months on PLP replacement, patients were 
ambulating with high‐stepping gait, unaided (Video 1). Furthermore, neuropathic pain 
has completely subsided; neither case requires additional analgesic medication.   
 
These results led to an improvement of 5 points in the Neurological Impairment Set (NIS) 
score in case (F1‐II‐5) and the 4 points in case F1‐II‐6 based on motor, pain and fatigue 
subsets.   Similarly, the CMT neuropathy score on PLP replacement improved by 4 points 
and 2 points in case F1‐II‐5 and F1‐II‐6 respectively (Supplemental data S5).   
 
Electrophysiology studies performed 18 months after PLP supplementation have 
demonstrated no disease progression with no significant changes in the motor and 
sensory responses. Whilst the distal motor responses are not significantly different from 
previous studies, the EMG of the proximal muscles shows motor unit recruitment and 
interference pattern improvement in the proximal muscles (quadriceps and tibialis 
anterior muscles, biceps and flexor carpi radialis) with activity present in the tibialis 
anterior that was un‐recordable on previous studies.  
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The clinical response to PLP replacement was further supported by measuring 
neurofilament light chain (NFL) protein in pre‐ and post‐ PLP replacement plasma from 
the PDXK cases in family 1. A reduction of NFL levels to the normal control range44 
(median 13 pg/mL, range 11‐18 pg/mL) (Figure 4C) occurred upon restoration of PLP 
levels and continued to improve with PLP supplementation. At 24 months with PLP 
supplementation, the NFL level was 2.5 times lower than before supplementation. 
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DISCUSSION 
Here we show that bi‐allelic mutations in PDXK lead to peripheral neuropathy with optic 
atrophy. We have shown previously that several inherited disorders affecting B6 vitamer 
metabolism, or resulting in inactivation of PLP, are implicated in neurological conditions. 
These include PNPO‐(MIM: 603287)46, ALDH7A1‐(MIM: 266100)47; 48 and PROSC‐
deficiency (MIM: 604436)49; 50 where the lack of PLP in the brain leads to early onset, 
vitamin B6‐dependent epilepsy refractory to anticonvulsants. In most cases, delayed 
vitamin B6 supplementation results in early death or severe handicap in these disorders. 
The PDXK activity is tissue‐specific under PLP‐deficiency conditions. In rats, B6 deficiency 
leads to rapid decreases in PDXK activity in the peripheries (liver, muscle and plasma) 
with maintained PDXK activity and B6 supply in the brain51; 52. This could explain the 
absence of seizures in humans with PDXK deficiency that present predominantly with 
peripheral nerve disease and normal CNS function.  Furthermore, our PDXK co‐expression 
networks analyses from peripheral nerve suggest a link to a module enriched for genes 
involved in oxidation‐reduction processes in which mitochondria plays a significant role. 
PLP is a cofactor for several mitochondrial enzymes, but it is not certain how PLP is 
transported into mitochondria in humans; in yeast there is evidence for involvement of 
Mtm1p53. Whilst we acknowledge that co‐expression networks generated from bulk RNA‐
seq of peripheral nerves are complex to interpret, there is growing evidence for the 
presence and importance of axonal RNA transport54‐56. Thus, our findings are interesting 
given the strong phenotypic similarity (optic atrophy and axonal polyneuropathy) to 
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other disorders caused by mutations in genes involved in mitochondrial functions 
associated with neurodegeneration such as OPA1 (MIM: 605290), DHTKD1 (MIM: 
614984), MFN1 (MIM:  608506) and MFN2 (MIM: 608507). Interestingly, within the PDXK 
regulon from the tibial nerve we found DHTKD1 already linked to Mendelian disorders 
and associated with primary peripheral axonal neuropathy57; 58. This data suggests that 
within this regulon there may be other genes involved in neuronal maintenance that 
could cause a similar disease phenotype to be discovered.   
 
Clinically, the PDXK‐related neuropathy presented with mixed sensory and motor 
involvement in early childhood and was associated with optic atrophy later in adulthood. 
Electrophysiologically, one of the earliest signs of the disease was the absence of sensory 
responses even when the motor responses were within normal limits as seen in family 2. 
We note that the patients with longstanding disease (family 1) had significant standing 
and walking difficulties despite a mild proximal motor deficit most likely due to the 
combination of severe distal motor involvement with severe proprioceptive impairment 
extending to the proximal joints exacerbated by the severely impaired vision59.  
Based on our collective experience in rare diseases, we acknowledge that it is very 
difficult to implement randomized case‐control studies for these patients and the 
subsequent limitations when designing therapeutic interventions. We would like to note 
that some clinical improvements seen in the patients reported here, such as pain and 
fatigue, are susceptible to placebo effects. Furthermore, the severity of the 
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polyneuropathy in the cases that received PLP supplementation and the absence of more 
proximal nerve‐conduction studies is a limitation for the characterization of the 
neurophysiological phenotype and response to treatment. However, whilst we are 
limited in our ability to fully explain the mechanism of clinical improvement the 
supplementation with PLP was associated with normalization of the biochemical profile 
and improved clinical outcomes in individuals F1‐II‐5 and F1‐II‐6. The clinical 
improvement was supported by the normalisation of PLP levels, stable 
electrophysiological picture and NFL normalisation after treatment. Furthermore, animal 
models of PDXK knockdown, B6 dietary deficiency and pharmacological models, all 
showed significant decreases in circulating PLP levels with reversible adverse effect(s) on 
the peripheral/sensory nerve similar to the human phenotype observed here (Table 3). 
The severe sensory involvement recorded at least 20 years before treatment, most likely 
accounted for the absence of a clinical effect on the sensory function in the two patients 
from family 1.  We are limited in our ability to fully quantify the potential for 
electrophysiological improvement at this stage in the disease due to severe axonal loss, 
short interval of PLP replacement and the absence of more proximal nerve‐conduction 
studies. Therefore, larger studies with treatment started earlier in the disease are 
warranted in order to assess the full potential benefit from treatment.  
 
Conclusion  
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We show that bi‐allelic mutations in PDXK cause autosomal recessive axonal peripheral 
polyneuropathy leading to disease via reduced PDXK enzymatic activity and low PLP. We 
show that the biochemical profile in affected individuals can be rescued with PLP 
supplementation and that this is associated with improvement in clinical scales. 
Therefore, we recommend that PDXK mutations should be screened for in patients with 
autosomal recessive, early‐onset polyneuropathy and supplementation with PLP should 
be started promptly with long‐term monitoring of clinical outcomes.  Furthermore, B6 
vitamers can be linked to diseases through a wide‐range of processes and genes involved 
in the vitamin B6 pathway. Therefore, our results can be extended to other neuropathies 
of different aetiology characterised by reduction of PLP levels or reduction of PLP‐
dependent enzyme activities. Collectively, these data expand the genetic causes of 
primary polyneuropathy and the heterogeneity of inborn errors of vitamin B6 metabolism 
and identifies PLP as a potential therapeutic target for this disorder.  
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FIGURE LEGEND 
Figure 1. Bi-allelic PDXK mutations are associated with axonal polyneuropathy and 
optic atrophy. 
A. Pedigree of the two families with PDXK mutations.  
B. Phenotype of the cases with PDXK mutations presenting with muscle atrophy of the 
intrinsic muscles of the hands with clawing of the hands, thin wrists, pes cavus and 
muscle atrophy in the feet and calves (B1‐B3 from case F1‐II‐5, B4‐B6 case F1‐II‐6).  
C. Fundoscopy confirmed bilateral optic disc atrophy in both cases (C1 for F1‐II‐5 and C2 
in F1‐II‐6).  
D. Nerve biopsy from case F1‐II‐6 showing axonopathy. There is diffuse and severe 
depletion of both small and large myelinated axons with most of the surviving axons 
being less than 5μm in diameter. There were no axonal ovoids but there were 
regenerating clusters (arrows) consistent with long standing indolent axonopathy. There 
is no demyelination process.  
E. Sanger sequencing confirming the homozygous c.682G>A mutation in two affected 
siblings and heterozygous state in unaffected family member in family 1 and homozygous 
c.659G>A in the two affected siblings and segregation in family 2.  
F. Vitamin B6 metabolic pathway. Phosphorylated B6 vitamers (PMP; pyridoxamine 5’‐
phosphate, PNP; pyridoxine 5’‐phosphate, PLP; pyridoxal 5’‐phosphate) present in the 
diet are hydrolysed to pyridoxal (PL), pyridoxamine (PM) and pyridoxine (PN) by intestinal 
phosphatases prior to absorption and then converted to their 5’‐phosphate derivatives in 
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the liver by pyridoxal kinase (PDXK). PNP and PMP are then converted to PLP, by 
pyridox(am)ine 5’‐phosphate oxidase (PNPO). PLP re‐enters the circulation bound to a 
lysine residue of albumin. Homeostatic regulation of tissue levels of PLP is achieved by 
various mechanisms, including feedback inhibition of PNPO and pyridoxal kinase by PLP60. 
Albumin in plasma, haemoglobin in erthyrocytes and glycogen phosphorylase in muscle 
also play a role, binding to PLP and helping to keep concentrations of this very reactive 
aldehyde low61 so as to avoid any unwanted reactions with biologically important 
molecules. Subsequent delivery of PLP to the tissues requires hydrolysis of circulating PLP 
to pyridoxal by the ecto‐enzyme tissue nonspecific alkaline phosphatase (TNSALP). The 
resulting pyridoxal is able to enter cells prior to being re‐phosphorylated by pyridoxal 
kinase to produce the active cofactor, PLP, required by B6‐dependent apoenzymes62. 
Within cells, recycling pathways also exist with PMP being oxidised by PNPO to form 
PLP61.  
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Figure 2. PDXK is highly expressed in peripheral and central nervous systems and in the 
same regulon with genes already linked to axonal peripheral neuropathies. 
A. Expression of PDXK in human tissues. Box and whisker plots showing the expression of 
PDXK across multiple human tissues.  Data generated by the GTEx consortium. Expression 
in tibial nerve is highlighted with a dark grey arrow and is amongst the tissues with the 
highest PDXK expression.  
B. Expression of PDXK in multiple cell types of the mouse central and peripheral nervous 
system generated using single cell RNA‐seq. PDXK gene expression across single cells 
isolated from the mouse central and peripheral nervous system and displayed using a 
heatmap demonstrates highest expression of this gene in neurons of the mouse 
hindbrain38 with expression in the peripheral neurons including sensory neurons. 
C. Top Down plot of the black module genes in the tibial nerve tissue. Only the most 
connected genes are shown. PDXK gene is highlighted in yellow. Genes known to be 
associated with GO term GO:0055114, oxidation‐reduction process are highlighted in red. 
Size of gene nodes reflects their connectivity with the rest of genes in the module. PDXK 
is amongst the top 60 most connected genes. Proximity of genes in the plot reflects their 
similarity in terms of shared connections with other genes.  Interestingly, within the PDXK 
regulon from the tibial nerve we found DHTKD1 already linked to Mendelian disorders 
and associated with primary peripheral axonal neuropathy57; 58.  
D. Conservation of p. Ala228Thr and p.Arg220Gln in PDXK across species.  
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E. Crystal structure of human pyridoxal kinase with bound ATP (PBS accession 3KEU). 
PDXK is a dimeric enzyme with one active site per monomer63 (monomers A and B are 
depicted in green and yellow, respectively). In the PDXK structure, the backbone‐carbonyl 
oxygen of Alanine 228 establishes a hydrogen bond with the adenine NH2 group of ATP. 
The active site of each monomer binds one ATP molecule, two Mg2+ ions and one Na2+ 
ion. The ATP binding site is composed of a β‐loop‐β structure, often referred as a flap, 
which provides numerous hydrogen‐bond interactions to the ATP β‐ and γ‐phosphates, 
and sequesters the ATP for catalysis.39 Arginine 220 is located in the β9, in the vicinity of 
ATP binding site. 
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Figure 3. PDXK mutations lead to reduced pyridoxal kinase enzymatic activity and low 
PLP. 
A. Circular dichroism analyses of recombinant PDXK WT and p.Ala228Thr mutant 
proteins. The left and right panels show the normalised far‐UV and near‐UV spectra of 
the two proteins, respectively. A clear difference in secondary structure content between 
the two proteins is observed from the far‐UV experiment.  
B. Analysis of the interaction of non‐hydrolysable analogue ATPγS with PDXK WT and 
p.Ala228Thr mutant proteins by ITC. The left panel shows the titration of ATPγS (250 μM) 
into a PDXK WT solution (25 μM). The thermogram shows that the interaction was 
entropically and enthalpically favoured, with ΔH ‐3.27 ± 0.42 kcal/mol, ‐TΔS ‐4.42 ± 0.48 
kcal/mol, KD 2.33 ± 0.25 µM and ΔG ‐7.69 ± 0.06 kcal/mol. The stoichiometry was 0.80 ± 
0.02 µM, indicating that each molecule of PDXK binds to one molecule of ATPγS. The right 
panel reports the titration of ATPγS (250 μM) into a PDXK p.Ala228Thr solution (25 μM). 
The experiment showed no interaction under the experimental conditions tested, 
suggesting that the mutation affected the ability of the kinase to bind the analogue 
substrate ATPγS.  
C. Western blot analysis shows normal expression of the PDXK protein in cases compared 
to controls. WT= wild‐type.  
D. Activity of recombinant wild‐type and p.Ala228Thr pyridoxal kinase protein measured 
as pyridoxal 5’‐phosphate formation.  Conditions: 0 – 100 µmol L‐1 pyridoxal (PL); 300 
µmol L‐1 MgATP; 20 mmol L‐1 potassium phosphate, pH 7.0; 37°C; 10 min incubation with 
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100 ng recombinant protein. Points displayed are a mean of three repeats. Vmax: WT = 
2.17 μmol L‐1 hr‐1; p.Ala228Thr = 2.52 μmol L‐1 h‐1. Km: WT = 14.53 μmol L‐1; p.Ala228Thr = 
31.93 μmol L‐1. 
E. Kinetics of recombinant wild‐type and p.Ala228Thr pyridoxal kinase protein upon 
variation of pyridoxal concentration. Pyridoxal kinase activity of recombinant human WT 
and p.Ala228Thr PDXK protein is measured as PLP formed after incubation with the 
substrate PL. Incubations performed in the presence of variable concentrations of MgATP 
(0 – 500 µmol/L) and 50 µmol/L pyridoxal. Kinetics were sigmoidal and parameters 
established were as follows: WT k0.5 = 53.4 µmol/L; Vmax = 16.8 pmol h‐1, p.Ala228Thr k0.5 = 
174.4 µmol/L; Vmax= 6.3 pmol h‐1. Results indicate a dramatic reduction in the catalytic 
efficiency of the p.Ala228Thr PDXK protein. n = 3 at each data point.   
F. Erythrocyte PDXK activity in dried blood spots from cases homozygous for the 
p.Ala228Thr and p.Arg220Gln versus controls (ages 15–92). Patients homozygous for 
p.Ala228Thr and p.Arg220Gln have lower activity than all controls. Activity measured as 
PLP formed after incubation of a 3mm dried blood spot punch with pyridoxal.  Each 
sample was analysed in duplicate and the mean is shown.  There was no correlation of 
PDXK activity with age. 
G‐H. Comparison of plasma PLP concentrations (retention time of 2.78/2.84 mins) in 
control (red) and cases carrying the PDXK mutation (blue) p.Arg220Gln (G) and 
p.Ala228Thr (H) show a significant reduction of PLP in the case samples (7.8 and 9 nmol/L 
respectively) vs control (control range 25‐75 nmol/L).   
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Figure 4. PLP supplementation in patients with PDXK mutations can rescue the 
biochemical phenotype.  
A.  Concentrations of plasma B6 vitamers in affected homozygous cases for p. Ala228Thr 
(F1‐II‐5), p.Arg220Gln (F2‐II‐2) and a heterozygous (F1‐III‐1) PDXK mutation carrier. The 
levels prior to supplementation were compared to published range of B6 vitamers in adult 
controls (n=523)64 not receiving PLP. PL, pyridoxal; PN, pyridoxine; PM, pyridoxamine; 
PLP, pyridoxal 5’‐phosphate; PNP, pyridoxine 5’‐phosphate; PMP, pyridoxamine 5’‐
phosphate; PA, 4‐pyridoxic acid. All units nmol/L, except for PNP which is stated in 
‘concentration units’. n.d, not detected; RI, reference interval; hom, homozygous; het‐
heterozygous.  
B. The effect of PLP supplementation on plasma PLP concentrations of a case with PDXK 
mutations. The red bar represents the PLP levels in a group of adult controls with no B6 
supplementation. There is a significant difference in the plasma PLP concentration of F1‐
II‐5 before supplementation (blue bar) and on PLP replacement (magenta bar) (***; p 
<0.05). The difference between groups was tested with the use of a one‐way analysis‐of‐
variance test followed by the Tukey‐Kramer test. The horizontal lines on the bars indicate 
mean values ±1 SD. 
C. Neurofilament light (NFL) concentrations in plasma from cases with homozygous 
p.Arg220Gln and p.Ala228Thr PDXK mutations and heterozygous carrier (F1‐III‐1). The 
blue bars show that NFL levels prior to PLP supplementation are high and consistent with 
values published in other inherited peripheral neuropathies44 (solid line) indicating on‐
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going axonal damage. The orange, grey and yellow bars shows the NFL levels in the cases 
from family 1 at 4, 12 and 24 months on PLP supplementation respectively. The levels 
have reduced to that of normal controls (dashed line) and continued to improve with 
longitudinal follow‐up suggesting an amelioration of the axonal breakdown.   
 
Table legends 
Table 1. Detailed description of the clinical phenotype associated with PDXK mutations.  
Table 2. Plasma B6 vitamer profiles for cases with PROSC, PNPO and PDXK deficiency 
supplemented with pyridoxal 5’‐phosphate 
Table 3. Vitamin B6‐related disease models  
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Phenotype/case F1-II-5 F1-II-6 F1-II-8 F2-II-1 F2-II-2Gender Male Female Female Female FemaleAge at examination (in years) 79 74 Died at 71 from leukaemia 31 29Demog
raphics Age at onset (in years) 7 9 7 5 2Symptoms at onset Lower limb weakness and wastingUpper limb weakness At 12 years At 12 years At 17 years 20s 20s
Progre
ssion Optic atrophy At 40 years At 47 years At 50 years 31 29Fundoscopy Pale optic discs bilaterally Pale optic discs bilaterally NA Mild optic disc pallor bilaterally Mild optic disc pallor bilaterallyOther cranial nerves NormalSkeletal deformities Pes cavus, hammer toes, clawing of hands Pes cavus, hammer toesPower Severe weakness of dorsi/plantar flexion, long finger extensors and intrinsic muscles of the hands Moderate-severe weakness of dorsi/plantar flexion, long finger extensors and mild weakness of intrinsic muscles of the handsMRC power score 44 44 56 54Reflexes Absent throughout. Mute plantar responses Areflexia.Mute plantar responses Areflexia. Mute plantar responsesReduced pain to mid calf and wrists Reduced pain to ankles and elbows Reduced pain to ankles Reduced pain to upper calf and base of fingersSensation Reduced vibration sense to iliac crest and wrist Reduced vibration sense to iliac crest and elbow Vibration decreased to the knees Vibration decreased to the kneesRomberg's sign Present Present Present PresentCoordination Normal Normal Normal NormalVisual acuities Unable to count fingers 6/12 in both eyes NA NAColour vision Unable to distinguish any colour Grossly impaired, 3/17 Ishihara plates 15/17 Ishihara plates 3/17 Ishihara platesPeripheral vision Normal Normal Normal NormalCognitive function Normal Normal Normal NormalNeurol
ogical e
xamina
tion
Seizures Absent Absent Absent AbsentMRI head Normal Normal NA NAOptic nerve and chiasm CT Normal Normal NA NA
Visual evoked 
potentials (VEP)
Severely attenuated bilaterally with anomalous waveform on flash VEP. NA NA
Somatosensory 
evoked potentials NA Poorly formed due to severe polyneuropathy NA NA
Nerve conduction 
study Severe sensori-motor axonal neuropathy Severe sensori-motor axonal neuropathy Severe sensori-motor axonal neuropathy Severe sensori-motor axonal neuropathy
Electromyography
Chronic denervation in a length dependent pattern. No myopathic changes. Chronic denervation in a length dependent pattern. No myopathic changes.Investi
gation 
results
Renal function Normal Normal Normal NormalLiver function Normal Normal Normal NormalGI tract Normal colonoscopy Normal Normal NormalPlasma amino acids Normal NA NA NAVitamin B1 (normal range 67-265 nmol/L) NA 176 149 183Vitamin B9 (normal range 3.9-20 ng/mL) Normal NA Normal NormalBioche
mical p
rofile 
Vitamin B12 (normal range 197-771 pg/mL) 938 454
NA
293 211
Legend: NA- not available, GI- gastrointestinal, na-not available, PLP- pyridoxal phosphate. 
Plasma amino acids tested: methionine, isoleucine, leucine, tyrosine, phenylalanine, 
ornithine, lysine, histidine, and arginine.
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Table 1. Detailed phenotype of the affected cases carrying PDXK mutations
Table 2. Plasma B6 vitamer profiles for patients with PROSC, PNPO and PDXK 
deficiency supplemented with pyridoxal 5’-phosphate.
Age B6 [dose] PLP PL PA PN PNP PMP PM
Control 
range* 
4.3 y – 
16 y
None 46 - 
321
5 - 18 16 - 
139
nd - 
0.6
nd nd - 9 nd
PROSC** 3 y PLP [70 mg 
QDS]
2769 796 2043 0.5 nd nd nd
PROSC** 6 m PLP [45 
mg/kg/day]
2166 1695 700 nd nd nd nd
PNPO***  2 y PLP [30 
mg/kg/d]
580 427 793 575 43 18 193
PNPO*** 10 y PLP [30 
mg/kg/d]
633 5798 7926 599 77 101 2731
PDXK****  79 y PLP [50 mg/d] 415 1550 1617 31 nd nd nd
Legend: nd; not detected. PL, pyridoxal; PN, pyridoxine; PM, pyridoxamine; PLP, 
pyridoxal 5’-phosphate; PNP, pyridoxine 5’-phosphate; PMP, pyridoxamine 5’-
phosphate; PA, 4-pyridoxic acid. All units nmol/L, except for PNP which is stated in 
‘concentration units’. Values outside the reference range are shown in bold. QDS = 
four times a day. *Control range as described in Footitt et al., 2013; ** Data from 
Darin et al., 2017. ***Data from Footitt et al., 2013. PLP doses received by PROSC 
and PNPO patients larger than the doses given to the PK-deficient patients (II-5 and 
II-6). ****Values at 12 months on treatment with PLP. 
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Table 3. Vitamin B6-related disease models
Model Phenotype Mechanism Effect on B6 pathway
Response to PLP 
supplementation
Pharmacological models
Isoniazid, levodopa, 
gentamicin, D-
penicillamine
Axonal peripheral 
neuropathy1
Interaction between the 
reactive aldehyde group of PLP 
with nucleophilic acceptors 
such as amine, hydrazine, 
hydroxylamine or sulphydryl 
groups rendering PLP inactive
Methylxanthines Axonal peripheral 
neuropathy2; 3
Directly inhibit enzymes 
involved in B6 metabolism
Carbamazepine, 
vigabatrin, sodium 
valproate
Axonal peripheral 
neuropathy4 5-7
Potent hepatic inducers of 
cytochrome P450, induce 
enzymes involved in the 
catabolism of PLP
Decrease in serum 
PLP
Prevents onset of 
peripheral 
neuropathy
B6 antivitamin 
Ginkgotoxin (4’-O-
methylpyridoxine)
Epileptic convulsions, leg 
paralysis and loss of 
consciousness8
Analogue of PLP. Inhibition of 
pyridoxal kinase by serving as 
an alternate substrate for the 
enzyme
Decrease in PLP 
formation
NA 
Animal models
Mouse Preweaning lethality 
(MGI:1351869)
PDXK knockout NA NA
Mouse Abnormal walking track 
patterns, axonal 
peripheral neuropathy 
with intact myelin on 
nerve biopsy9
PLP dietary-deficient Decrease in serum 
PLP
Complete reversal 
of symptoms with 
PLP 
supplementation 
Rat Tissue-specific  PDXK 
response to B6 deficiency 
10; 11
B6 diet deficient PDXK activity 
rapidly decreases in 
the liver, muscle 
and plasma 
compared to the 
brain
Reversal with PLP 
supplementation
C. elegans Sensory-motor 
integration deficit in 
neuromuscular behaviour 
12
PDXK knockout NA Rescued by 
expression of a WT 
transgene.
Drosophila Motility and eye 
dysfunction with 
compromised climbing 
ability, ommatidial array 
disruption and decreased 
longevity13
PDXK knockdown by RNA 
interference
 
NA Rescued by 
expression of a WT 
transgene. 
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